Bosutinib/Bosutinib usage and dosage

Bosutinib/Bosutinib is a targeted drug mainly used to treat newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (CP Ph+CML); or patients aged 1 year and above with chronic phase, accelerated phase (AP) or blast phase (BP) Ph+CML, and cases of drug resistance or intolerance to previous treatments.

The recommended use of bosutinib is to take it orally once daily with a meal. The tablet should be swallowed whole and should not be broken or cut. The specific dosage is as follows:

1. Adult patients:

(1) For newly diagnosed CP Ph+CML patients, the recommended starting dose is 400 mg daily;

(2) For patients with Ph+ CML in chronic, accelerated or blast phase, and patients who are resistant or intolerant to previous therapy: the recommended starting dose is 500 mg daily.

2. Pediatric patients:

(1) For newly diagnosed CP Ph+CML patients, the recommended dose is 300mg/m2;

(2) For patients with CP Ph+CML who are resistant or intolerant to previous treatments, the recommended dose is 400mg/m2.

During the patient's treatment, if adverse reactions occur or the expected therapeutic effect fails to be achieved, the doctor may adjust or increase the dosage according to the patient's specific condition. For patients who achieve or maintain a response, consider increasing the dose by 100 mg each time, up to a maximum of 600 mg daily.

For patients who are unable to swallow capsules, the contents of the capsules can be mixed with applesauce or yogurt. Remove the desired number of capsules from the container, prepare the dose as directed, and prepare room temperature applesauce or yogurt in a clean container. Carefully open each capsule and add the entire contents of each capsule to the applesauce or yogurt, then mix the entire dose into the applesauce or yogurt. Patients should consume the entire mixture immediately without chewing. Do not store the mixture for later use. Do not take additional doses if the entire preparation is not swallowed. Wait until the next day to resume dosing.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adc84ad5-a04d-4fee-9ba8-91f7abd928e3